瑞康醫藥(002589.SZ)擬收購威海衡健醫院72%股份及內蒙古包氏蒙醫國際整骨醫院70%股份
格隆匯10月31日丨瑞康醫藥(002589.SZ)公佈,公司擬使用自有資金購買威海衡健醫院管理有限公司72%的股份,以北京天元開資產評估有限公司2019年10月28日出具的《瑞康醫藥集團股份有限公司擬股權收購涉及的威海市衡健醫院管理有限公司股東全部權益價值項目資產評估報告》(天圓開評報字[2019]第000258號)作為交易依據,收購價合計人民幣4287.78萬元。
公司擬使用自有資金購買內蒙古包氏蒙醫國際整骨醫院有限公司70%的股份,以北京天元開資產評估有限公司2019年10月28日出具的《瑞康醫藥集團股份有限公司擬股權收購涉及的內蒙古包氏蒙醫國際整骨醫院有限公司股東全部權益價值項目資產評估報告》(天圓開評報字[2019]第000257號)作為交易依據,收購價合計人民幣687.4萬元。
此次交易構成了關聯交易,公司於2019年10月30日召開第四屆董事會第一次會議,審議通過了《關於收購威海衡健醫院管理有限公司72%的股份暨關聯交易的議案》,由於威海衡健醫院管理有限公司的實際控制人為公司控股股東韓旭、張仁華夫婦,故關聯董事張仁華、韓旭、韓春林迴避表決。
公司於2019年10月30日召開第四屆董事會第一次會議,審議通過了《關於收購內蒙古包氏蒙醫國際整骨醫院有限公司70%的股份暨關聯交易的議案》,由於此次收購內蒙古包氏蒙醫國際整骨醫院有限公司70%的股份系公司控股股東張仁華以及其子韓春林的股份,故關聯董事張仁華、韓旭、韓春林迴避表決。獨立董事出具事前認可的書面意見並對上述關聯交易發表了同意的獨立意見。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.